# Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

> **NCT07191717** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 42 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Invasive Breast Carcinoma
- Localized Estrogen Receptor-Positive Breast Carcinoma
- Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Imlunestrant
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Radiologic Imaging Procedure

## Key facts

- **NCT ID:** NCT07191717
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2030-04-30
- **Final completion:** 2031-04-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07191717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07191717, "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07191717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*